NEWS
Addex and Indivior Select Clinical Candidates from GABAB
Positive Allosteric Modulator
Research Collaboration (GlobeNewswire)
Positive Allosteric Modulator
Research Collaboration (GlobeNewswire)
Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and Indivior PLC (NASDAQ/LSE: INDV) today announced the selection of clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration.
Indivior has selected a compound for future development in substance use disorder and will now undertake all future development of their selected compound.
Under the terms of the agreement, Addex is eligible for payment of up to USD 330 million on successful achievement of prespecified regulatory, clinical and commercial milestones as well as tiered royalties on the level of net sales from high single digits up to low double-digit. Under the terms of the agreement, Addex has also exercised its right to select a compound to advance its own independent GABAB PAM program for the treatment of chronic cough.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1281Followers
77Following
9045Visitors
Follow